MSME (Udyam registered) Ministry of MSME
- Category
- Small (2020-21)
- Udyam number
- UDYAM-TS-02-0015523
Market Cap
₹33.73 Cr
VISTAPH · BSE
Share Price
₹5.62
+2.55% today
Revenue
₹5.40 Cr
FY 2025-26 · -46.4% YoY
EBITDA
−₹14.62 Cr
Margin -270.7%
Net Profit
−₹12.06 Cr
FY 2025-26 · -158.8% YoY
Authorised capital
₹15 Cr
Registered with MCA
Paid-up capital
₹12.31 Cr
Issued & subscribed
Open charges
₹17 Cr
Satisfied ₹16.08 Cr
About Vista Pharmaceuticals Ltd.
Data last updated:
Vista Pharmaceuticals Ltd. is a public limited company based in Nalgonda, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 25 January 1991 and has been in existence for over 35 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24239TG1991PLC012264. Its GSTIN is 36AAACV7648G1Z2 (Telangana). The company holds 3 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 524711.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹12.31 Cr. It is led by directors including Murali Meraga (Managing Director) and Pavan Sathvik Gilaka (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Nalgonda, Telangana.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹5.4 Cr, a decline of 46.4% compared to the previous year. For the same year it recorded a net loss of ₹12.06 Cr (net margin -223.3%) and EBITDA of -₹14.62 Cr (EBITDA margin -270.7%).
The company is associated with 1 brand: Vista Pharmaceuticals. As per MCA filings, the company has open charges of ₹17 Cr and satisfied charges of ₹16.08 Cr on record. Court records list 8 cases involving the company, including 1 filed by the company and 7 filed against it; 2 cases are pending. The company has 42 deals on record (42 market trades); the latest was in June 2024. Its 5 peer companies in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 3 smaller; the largest is Medioint Lifescience Private Limited with revenue of ₹10.68 Cr. The company has 6 MSME Form 1 returns on record between 2017 and 2021, listing 28 overdue payments to 17 micro and small suppliers.
Vista Pharmaceuticals Ltd. is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0015523). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website vistapharmaceuticals.com.
Company details
CIN L24239TG1991PLC012264
Registration Number 012264
Incorporation Date 25 January 1991
ROC Hyderabad
Listing Status Listed - Listed on BSE (524711)
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-TS-02-0015523
CIN history
Vista Pharmaceuticals has one previous CIN (Corporate Identification Number): L24239AP1991PLC012264. The current CIN is L24239TG1991PLC012264, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24239TG1991PLC012264 | Current |
| L24239AP1991PLC012264 | Previous |
Key People
Murali Meraga Managing Director Pavan Sathvik Gilaka Whole-Time Director Dhananjaya Alli Whole-Time Director Recognitions & Rankings of Vista Pharmaceuticals
Contact details
Vista Pharmaceuticals Ltd.'s registered office is in Nalgonda, Telangana. Its website is vistapharmaceuticals.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressPlot Nos.10 To 14 And 16 To 20 Apiic Industrial Estate Chityal Gop, Alaipalli, Nalgonda, Telangana, India – 508254
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Vista Pharmaceuticals Ltd., buy the company report.
Comprehensive company report
Vista Pharmaceuticals Ltd. - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Vista Pharmaceuticals operates one associated brand: Vista Pharmaceuticals. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of OTCs and generic prescription products | vistapharmaceuticals.com |
Business activity
The main business activity of Vista Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Vista Pharmaceuticals Ltd., buy the company report.
Financials of Vista Pharmaceuticals Ltd.
FY 2025-26 filings availableVista Pharmaceuticals Ltd. reported revenue of ₹5.4 Cr (down 46.4% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹5.40 Cr
-46.4% YoY
EBITDA
−₹14.62 Cr
-262.8% YoY
Profit After Tax
−₹12.06 Cr
-158.8% YoY
Net Worth
-
Total Assets
-
Total Debt
-
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 5.40 | 10.07 | 10.29 | 1.00 | 0.39 | 1.27 | 22.76 |
| Revenue growth | -46.4% | -2.1% | +929.0% | +156.4% | -69.3% | -94.4% | - |
| EBITDA | (14.62) | (4.03) | (3.55) | (4.32) | (1.28) | (1.73) | (4.80) |
| EBITDA margin | -270.7% | -40.0% | -34.5% | -432.0% | -328.2% | -136.2% | -21.1% |
| Profit before tax | (16.15) | (5.30) | (5.18) | (5.88) | (2.63) | (3.81) | (3.94) |
| Net profit | (12.06) | (4.66) | (4.25) | (5.67) | (0.90) | (2.01) | (3.68) |
| Net profit margin | -223.3% | -46.3% | -41.3% | -567.0% | -230.8% | -158.3% | -16.2% |
| EPS (₹) | (1.96) | (0.76) | (0.96) | (1.51) | (0.24) | (0.55) | (1.21) |
| Balance sheet | |||||||
| Total assets | - | 52.95 | 48.52 | 46.73 | 48.08 | 43.63 | 45.16 |
| Net worth | - | 45.42 | 40.46 | 36.71 | 35.45 | 32.85 | 29.64 |
| Total debt | - | 7.40 | 7.96 | 9.96 | 12.55 | 10.71 | 15.47 |
| Cash & bank | - | 0.73 | 0.09 | 0.20 | 0.07 | 0.14 | 0.23 |
| Net working capital | - | 17.55 | 13.93 | 14.44 | 16.04 | 8.01 | 15.22 |
| Cash flow | |||||||
| Cash from operations | - | (6.98) | (4.91) | (1.71) | (0.99) | (6.75) | 0.80 |
| Cash from investing | - | (0.44) | (0.79) | (1.27) | (0.01) | (0.30) | (1.73) |
| Cash from financing | - | 8.06 | 5.59 | 3.11 | 0.94 | 6.96 | 0.28 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.42 | 1.46 | 1.52 | 3.23 | 2.56 | 2.49 |
| Revenue growth (YoY) | -100.0% | -100.0% | -5.5% | -41.4% | -15.6% | - | - | - |
| Other income | 0.04 | 0.03 | 0.09 | 0.19 | 0.00 | 0.24 | 0.12 | 0.01 |
| Total expenses | 0.84 | 7.06 | 5.42 | 4.90 | 2.63 | 4.14 | 4.07 | 3.32 |
| EBITDA | (0.84) | (7.06) | (3.00) | (3.44) | (1.11) | (0.91) | (1.51) | (0.83) |
| EBITDA margin | - | - | -124.0% | -235.6% | -73.0% | -28.2% | -59.0% | -33.3% |
| Depreciation | 0.19 | 0.19 | 0.19 | 0.20 | 0.18 | 0.18 | 0.19 | 0.18 |
| Interest | 0.34 | 0.55 | 0.18 | 0.18 | 0.19 | 0.21 | 0.22 | 0.25 |
| Profit before tax | (1.33) | (7.77) | (3.28) | (3.63) | (1.48) | (1.06) | (1.80) | (1.25) |
| Tax | (0.34) | (1.91) | (0.96) | (1.03) | (0.19) | 0.43 | (0.48) | (0.28) |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 24 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 2.42 | 1.46 | 1.52 | 3.23 | 2.56 | 2.49 |
| Revenue growth (YoY) | -100.0% | -100.0% | -5.5% | -41.4% | -15.6% | - | - | - |
| Other income | 0.04 | 0.03 | 0.09 | 0.19 | 0.00 | 0.24 | 0.12 | 0.01 |
| Total expenses | 0.84 | 7.06 | 5.42 | 4.90 | 2.63 | 4.14 | 4.07 | 3.32 |
| EBITDA | (0.84) | (7.06) | (3.00) | (3.44) | (1.11) | (0.91) | (1.51) | (0.83) |
| EBITDA margin | - | - | -124.0% | -235.6% | -73.0% | -28.2% | -59.0% | -33.3% |
| Depreciation | 0.19 | 0.19 | 0.19 | 0.20 | 0.18 | 0.18 | 0.19 | 0.18 |
| Interest | 0.34 | 0.55 | 0.18 | 0.18 | 0.19 | 0.21 | 0.22 | 0.25 |
| Profit before tax | (1.33) | (7.77) | (3.28) | (3.63) | (1.48) | (1.06) | (1.80) | (1.25) |
| Tax | (0.34) | (1.91) | (0.96) | (1.03) | (0.19) | 0.43 | (0.48) | (0.28) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 5.40 | 10.07 | 10.29 | 1.00 | 0.39 | 1.27 | 22.76 |
| Revenue growth | -46.4% | -2.1% | +929.0% | +156.4% | -69.3% | -94.4% | - |
| Other income | 0.32 | 0.44 | 0.33 | 0.40 | 0.17 | 0.20 | 3.75 |
| Total expenses | 20.02 | 14.10 | 13.84 | 5.32 | 1.67 | 3.00 | 27.56 |
| Employee cost | 0.00 | 2.00 | 1.79 | 0.51 | 0.57 | 1.15 | 1.31 |
| EBITDA | (14.62) | (4.03) | (3.55) | (4.32) | (1.28) | (1.73) | (4.80) |
| EBITDA margin | -270.7% | -40.0% | -34.5% | -432.0% | -328.2% | -136.2% | -21.1% |
| Depreciation | 0.75 | 0.74 | 0.72 | 0.62 | 0.62 | 0.73 | 1.35 |
| Interest | 1.10 | 0.97 | 1.24 | 1.34 | 0.90 | 1.55 | 1.54 |
| Profit before tax | (16.15) | (5.30) | (5.18) | (5.88) | (2.63) | (3.81) | (3.94) |
| Tax | (4.09) | (0.64) | (0.67) | (0.21) | (1.73) | (1.80) | (0.26) |
| Net profit | (12.06) | (4.66) | (4.25) | (5.67) | (0.90) | (2.01) | (3.68) |
| Net profit margin | -223.3% | -46.3% | -41.3% | -567.0% | -230.8% | -158.3% | -16.2% |
| EPS (₹) | (1.96) | (0.76) | (0.96) | (1.51) | (0.24) | (0.55) | (1.21) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 12.31 | 9.43 | 7.51 | 7.36 | 7.36 | 6.07 |
| Reserves & surplus | - | 33.10 | 26.22 | 23.04 | 28.09 | 25.49 | 23.57 |
| Shareholders' funds (net worth) | - | 45.42 | 40.46 | 36.71 | 35.45 | 32.85 | 29.64 |
| Secured loans | - | 7.40 | 7.96 | 9.96 | 12.55 | 11.26 | 15.47 |
| Unsecured loans | - | 0.00 | 0.00 | 0.00 | 0.00 | (0.55) | 0.00 |
| Total debt | - | 7.40 | 7.96 | 9.96 | 12.55 | 10.71 | 15.47 |
| Total liabilities | - | 52.95 | 48.52 | 46.73 | 48.08 | 43.63 | 45.16 |
| Assets | |||||||
| Gross block | - | 27.18 | 27.06 | 26.76 | 25.74 | 25.72 | 25.72 |
| Net block | - | 18.70 | 19.32 | 19.74 | 19.33 | 19.93 | 20.66 |
| Capital work in progress | - | 10.14 | 9.82 | 9.33 | 9.08 | 9.08 | 8.78 |
| Investments | - | 0.05 | 0.02 | 0.02 | 0.03 | 0.04 | 0.02 |
| Inventories | - | 8.22 | 6.79 | 7.68 | 9.33 | 9.68 | 9.68 |
| Sundry debtors | - | 13.54 | 14.28 | 11.25 | 10.46 | 2.17 | 10.28 |
| Cash & bank balances | - | 0.73 | 0.09 | 0.20 | 0.07 | 0.14 | 0.23 |
| Loans & advances | - | 2.41 | 2.23 | 4.62 | 3.70 | 3.25 | 1.00 |
| Total current assets | - | 24.90 | 23.39 | 23.75 | 23.56 | 15.24 | 21.19 |
| Total current liabilities | - | 7.35 | 9.46 | 9.31 | 7.52 | 7.23 | 5.97 |
| Net working capital | - | 17.55 | 13.93 | 14.44 | 16.04 | 8.01 | 15.22 |
| Total assets | - | 52.95 | 48.52 | 46.73 | 48.08 | 43.63 | 45.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 0.09 | 0.20 | 0.07 | 0.14 | 0.23 | 0.87 |
| Net cash from operating activities | - | (6.98) | (4.91) | (1.71) | (0.99) | (6.75) | 0.80 |
| Net cash from investing activities | - | (0.44) | (0.79) | (1.27) | (0.01) | (0.30) | (1.73) |
| Net cash from financing activities | - | 8.06 | 5.59 | 3.11 | 0.94 | 6.96 | 0.28 |
| Net change in cash | - | 0.64 | (0.11) | 0.13 | (0.07) | (0.09) | (0.64) |
| Closing cash | - | 0.73 | 0.09 | 0.20 | 0.07 | 0.14 | 0.23 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -46.4% | -2.1% | +929.0% | +156.4% | -69.3% | -94.4% | - |
| EBITDA growth | -262.8% | -13.5% | +17.8% | -237.5% | +26.0% | +64.0% | - |
| PBT growth | -204.7% | -2.3% | +11.9% | -123.6% | +31.0% | +3.3% | - |
| Net income growth | -158.8% | -9.7% | +25.0% | -530.0% | +55.2% | +45.4% | - |
| Revenue CAGR (3Y) | +75.4% | +195.6% | +100.9% | -64.7% | -76.8% | -64.7% | -2.0% |
| EBITDA CAGR (3Y) | +50.1% | +46.6% | +27.1% | -3.5% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | -223.3% | -46.3% | -43.8% | -567.0% | -230.8% | -158.3% | -16.2% |
| Return on capital employed | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -5.2% |
| Return on net worth | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -11.3% |
| Debt / equity | - | 0.18 | 0.23 | 0.31 | 0.34 | 0.42 | 0.41 |
| Long-term debt / equity | - | 0.06 | 0.11 | 0.17 | 0.24 | 0.24 | 0.18 |
| Interest cover | -7.16 | -20.34 | -29.04 | -27.13 | -47.37 | -63.01 | -25.04 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.37 | 0.38 | 0.04 | 0.02 | 0.05 | 0.91 |
| Inventory turnover | - | 1.34 | 1.42 | 0.12 | 0.04 | 0.13 | 2.17 |
| Debtors turnover | - | 0.72 | 0.81 | 0.09 | 0.06 | 0.20 | 2.44 |
| EPS (₹) | (1.96) | (0.76) | (0.96) | (1.51) | (0.24) | (0.55) | (1.21) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 7.38 | 7.56 | 8.13 | 9.64 | 8.93 | 9.76 |
To see the full year-wise statements and ratios of Vista Pharmaceuticals Ltd., buy the company report.
Board of directors of Vista Pharmaceuticals Ltd.
Vista Pharmaceuticals has 9 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Umakanth Katta | Director | 13 Jul 2020 | 6 Years 3 Months | Current |
| Pavan Sathvik Gilaka Also directs: Mavone Infrastructure Private Limited | Whole-Time Director | 14 Oct 2022 | 4 Years 0 Months | Current |
| Murali Meraga | Managing Director | 14 Oct 2022 | 4 Years 0 Months | Current |
| Mallem Hanumantha Rao | Director | 16 Sep 1993 | 33 Years 1 Months | Current |
| Dhananjaya Alli | Whole-Time Director | 07 Sep 2015 | 11 Years 1 Months | Current |
| Stanley Prabhakar Reddy | Director | 12 Aug 2016 | 10 Years 2 Months | Current |
Showing 6 of 9 current directors. View all directors
Peer comparison
Vista Pharmaceuticals Ltd. is compared with the 5 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Medioint Lifescience Private Limited | ₹10.68 Cr (FY 2025) | -1.0% | Dhar, Madhya Pradesh, India | |||
| Pharm Products Private Limited | ₹10.64 Cr (FY 2025) | 8.0% | Thanjavur, Tamil Nadu, India | |||
| Pharmtech Solutions Private Limited | ₹10.59 Cr (FY 2019) | 397.0% | Hyderabad, Telangana, India | |||
| Salus Laboratories Private Limited | ₹10.59 Cr (FY 2024) | 45.0% | Madhura Nagar, Telangana, India | |||
| Biowin Healthcare Limited | ₹10.57 Cr (FY 2025) | -3.0% | Ahmedabad, Gujarat, India | |||
| Vista Pharmaceuticals Ltd.this company | ₹5.4 Cr (FY 2026) | -₹12.06 Cr | -223.3% | -46.4% | Nalgonda, Telangana, India |
To see the full peer comparison of Vista Pharmaceuticals Ltd., buy the company report.
Auditor
Vista Pharmaceuticals Ltd. is audited by A.M.REDDY & D.R.REDDY for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| A.M.REDDY & D.R.REDDY | FY 2023 | 009068S |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 21.20%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 78.80%.
Mar 2026
QUARTER
21.20% Promoters
78.80% Retail & Others
Promoter holding - history
Now 21.20% · Mar 2026High 21.20% · Jun 2025Low 21.20% · Jun 2025
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 21.20% | 21.20% | 21.20% | 21.20% |
| Public | 78.80% | 78.80% | 78.80% | 78.80% |
Charges & borrowings
Open charges
₹17 Cr
Satisfied charges
₹16.08 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 23 Feb 2017 | 100091777 | Vijaya Bank | ₹17 Cr | Open | |
| 25 Jun 2015 | 10578333 | State Bank of India | ₹8 Cr | Satisfied | |
| 02 May 2014 | 10493023 | Allahabad Bank | ₹4 Cr | Satisfied | |
| 16 Oct 1995 | 90139978 | State Bank of Hyderabad | ₹1.1 Cr | Satisfied | |
| 12 Sep 1994 | 90137644 | State Bank of Hyderabad | ₹2.08 Cr | Satisfied |
To see the full charge records of Vista Pharmaceuticals Ltd., buy the company report.
Total charge records: 6 View all charges
Deals & funding
Vista Pharmaceuticals Ltd. has 42 deals on record (42 market trades); the latest was in June 2024.
Total deals
42
Market trades
42
Deals on record (5 of 42)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2022 | Market trade | ₹51.2 Lakh | Buyer: Multiplier Share and Stock Advisors Private Limited Seller: Multiplier Share and Stock Advisors Private Limited |
| Mar 2018 | Market trade | ₹2.4 Cr | Buyer: NBN Fintrade Private Limited Seller: NBN Fintrade Private Limited , an individual |
| Jan 2006 | Market trade | ₹70.1 Lakh | Buyer: Master Finlease Limited Seller: Vista Pharmaceuticals Inc, Master Finlease Limited |
| Jan 2006 | Market trade | ₹73.8 Lakh | Buyer: Master Finlease Limited Seller: Vista Pharmaceuticals Inc, Master Finlease Limited |
| Jan 2006 | Market trade | ₹84.5 Lakh | Buyer: Mehta A.P Huf, Master Finlease Limited Seller: Vista Pharmaceuticals Inc, Master Finlease Limited |
To see the full deal history of Vista Pharmaceuticals Ltd., buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Vista Pharmaceuticals Ltd. has 8 court cases on record: 1 filed by Vista Pharmaceuticals, 7 filed against it. 2 cases are pending and 6 are disposed.
Total cases
8
Filed by the company
1
Filed against the company
7
Pending
2
Disposed
6
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 5 | 5 | 2 |
| High courts | 2 | 1 | 0 |
| Supreme Court | 1 | 1 | 0 |
Cases on record (5 of 8)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summons Cases SS) | Filed against the company by M/S Rhenus Logistics India Pvt Ltd. | Pending |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by M/S. Chromachemie Laboratory Pvt Ltd. | Disposed |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by M/S. Chromachemie Laboratory Pvt Ltd. | Disposed |
| District court, Hyderabad CCC, Telangana | Court case (S.O.P) | Filed against the company by an individual | Disposed |
| High Court, TELANGANA | Company petition | Filed by the company | Disposed |
To see the full case history of Vista Pharmaceuticals Ltd., buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Credit ratings & regulatory alerts
Vista Pharmaceuticals Ltd. was last rated by Indiarating on 09 Aug 2021.
| Rating agency | Rated on | Rating |
|---|---|---|
| Indiarating | 09 Aug 2021 |
To see the full credit ratings and regulatory alerts of Vista Pharmaceuticals Ltd., buy the company report.
MSME payment delays
Vista Pharmaceuticals Ltd. has 6 MSME Form 1 returns on record between 2017 and 2021, listing 28 overdue payments to 17 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 17)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| Newzen Facility Services | |||
| Dun & Bradstreet Information Services India Private Limited | |||
| an individual supplier | |||
| Team Tranquil Software Solutions Private Limited |
To see the full MSME payment records of Vista Pharmaceuticals Ltd., buy the company report.
Individuals and sole proprietors among the suppliers are not named.
GST
Vista Pharmaceuticals has 3 GST registrations: 1 active and 2 cancelled or inactive.
Total GSTINs
3
Active
1
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAACV7648G1Z2 | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Vista Pharmaceuticals Ltd., buy the company report.
Recent activity
Vista Pharmaceuticals Ltd. has 21 board changes on record since 1993: 15 appointments and 6 cessations. The latest: Murali Meraga was appointed as Managing Director on 14 Oct 2022.
Filing
Vista Pharmaceuticals Ltd. has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
AGM
Vista Pharmaceuticals Ltd. last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Appointed
Murali Meraga was appointed as Managing Director.
Appointed
Pavan Sathvik Gilaka was appointed as Whole-Time Director.
Ceased
Narendra Gilaka ceased to be Director.
Ceased
Anand Chittajallu ceased to be Director.
Appointed
Umakanth Katta was appointed as Director.
Ceased
Venkata Chalapathi Rao Naraparaju ceased to be Whole-Time Director.
Appointed
Divakar Reddy Yerrabommanahalli was appointed as Director.
Ceased
Vatti Vani ceased to be Director.
Ceased
Rajendra Prasad Kandikattu ceased to be Nominee Director.
Charges
A charge with Vijaya Bank of Rs. 17.00 Cr registered on 23 Feb 2017 with Charge ID 100091777 was modified on 17 Apr 2018.
24 earlier events are in the company report.
News
Frequently asked questions
Vista Pharmaceuticals is an active public limited company based in Nalgonda, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 25 January 1991 (35+ years old) and is registered under CIN L24239TG1991PLC012264. Listed on BSE: 524711.
Vista Pharmaceuticals reported revenue of ₹5.4 Cr for FY 2025-26 (down 46.4% YoY) based on standalone financials.
Vista Pharmaceuticals has 9 current directors:
- Murali Meraga - Managing Director
- Pavan Sathvik Gilaka - Whole-Time Director
- Dhananjaya Alli - Whole-Time Director
- Umakanth Katta - Director
- Mallem Hanumantha Rao - Director
- Stanley Prabhakar Reddy - Director
- Umesh Virupakah Banakar - Director
- Divya Bhavani Chakravarthula - Director
- Divakar Reddy Yerrabommanahalli - Director
The latest financial statements of Vista Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.
The GSTIN of Vista Pharmaceuticals is 36AAACV7648G1Z2, registered in Telangana. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Vista Pharmaceuticals is L24239TG1991PLC012264. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Vista Pharmaceuticals is a listed company as per MCA records. Its shares are listed on BSE (code: 524711).
Vista Pharmaceuticals has 8 court cases on record: 1 filed by the company and 7 filed against it. 2 are pending. Most are in the district courts.
Vista Pharmaceuticals was incorporated on 25 January 1991, making it 35+ years old. It is registered with the Registrar of Companies, Hyderabad.
Vista Pharmaceuticals has 42 deals on record (42 market trades); the latest was in June 2024.
The peers of Vista Pharmaceuticals by revenue are Medioint Lifescience Private Limited, Pharm Products Private Limited, Pharmtech Solutions Private Limited, Salus Laboratories Private Limited, Biowin Healthcare Limited, all in the Pharma industry (Formulations, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Murali Meraga was appointed as Managing Director on 14 Oct 2022. Pavan Sathvik Gilaka was appointed as Whole-Time Director on 14 Oct 2022. Narendra Gilaka ceased to be Director on 08 Sep 2022. Vista Pharmaceuticals has 21 board changes on record in total.